This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, H. Articles by Hersh, E. M. Search for Related Content PubMed PubMed Citation Articles by Zhang, H. Articles by Hersh, E. M.

A Human Monoclonal Antimelanoma Single-Chain Fv Antibody Derived from Tumor-infiltrating Lymphocytes¹

Department of Microbiology and Immunology, Section of Hematology and Oncology [H. Z., D. F. L., R. M. B.], Department of Medicine, Arizona Cancer Center [J. A. M. B., E. M. H.], and Department of Biochemistry [W. J. G.], University of Arizona, Tucson, Arizona 85724

With the development of recombinant DNA technology, it has become feasible to clone, construct, and express fully human immunoglobulin molecules. Here we report a novel methodology to make human antitumor single-chain Fv (scFv) antibodies from tumor-infiltrating B lymphocytes. We isolated and expanded tumor-infiltrating B lymphocytes from melanomas in the presence of Epstein-Barr virus. The transformed B cells secreting tumor-specific antibodies were identified and cloned by limiting dilution. From one B cell clone with specific melanoma reactivity, we captured the immunoglobulin variable region genes V_H and V_k by PCR, sequenced the genes, and linked them together by PCR assembly with the use of a (Gly4Ser)₃ linker. The scFv gene was then cloned into the pET21d vector and expressed. The obtained scFv protein with a M_r of 29,000 was purified and biotinylated for further characterization. The scFv demonstrated specific tumor reactivity to 21 of 24 different melanoma cell lines and not to 14 nonmelanoma tumor cell lines, such as breast, ovarian, and colon cancer cells lines; normal human melanocytes as well as normal human leukocytes. These results were obtained in (a) a tumor cell ELISA, (b) fixed cell immunofluorescence, and (c) live cell flow cytometry. The immunoprecipitation results indicated that a protein antigen of M_r 45,000 was recognized by the scFv. Since we reported previously that about 70% of human tumors of different histological types contain tumor-infiltrating B lymphocytes producing specific antitumor antibodies, this approach offers a rapid, effective method by combining in vitro B-cell expansion and PCR gene cloning to elucidate the repertoire of the human antitumor immune response and to make human monoclonal antitumor antibody molecules.

¹ Supported by a grant from the Share Foundation.

² To whom requests for reprints should be addressed, at Section of Hematology and Oncology, Arizona Cancer Center, Tucson, AZ 85724.

Received 2/13/95. Accepted 5/18/95.

This article has been cited by other articles:

				B. Kotlan, P. Simsa, J.-L. Teillaud, W. H. Fridman, J. Toth, M. McKnight, and M. C. Glassy Novel Ganglioside Antigen Identified by B Cells in Human Medullary Breast Carcinomas: The Proof of Principle Concerning the Tumor-Infiltrating B Lymphocytes J. Immunol., August 15, 2005; 175(4): 2278 - 2285. [Abstract] [Full Text] [PDF]

				D. B. Rubinstein, A. Stortchevoi, M. Boosalis, R. Ashfaq, and T. Guillaume Overexpression of DNA-binding Protein B Gene Product in Breast Cancer as Detected by in Vitro-generated Combinatorial Human Immunoglobulin Libraries Cancer Res., September 1, 2002; 62(17): 4985 - 4991. [Abstract] [Full Text] [PDF]

				J. A. Coronella, C. Spier, M. Welch, K. T. Trevor, A. T. Stopeck, H. Villar, and E. M. Hersh Antigen-Driven Oligoclonal Expansion of Tumor-Infiltrating B Cells in Infiltrating Ductal Carcinoma of the Breast J. Immunol., August 15, 2002; 169(4): 1829 - 1836. [Abstract] [Full Text] [PDF]

				L. Mazzucchelli, J. B. Burritt, A. J. Jesaitis, A. Nusrat, T. W. Liang, A. T. Gewirtz, F. J. Schnell, and C. A. Parkos Cell-Specific Peptide Binding by Human Neutrophils Blood, March 1, 1999; 93(5): 1738 - 1748. [Abstract] [Full Text] [PDF]